Akebia Therapeutics Reports Third-Quarter 2026 Results
Akebia said patients on Vafseo (vadadustat) increased to approximately 11,500 at the end of Q3 2026.
Related stories
Lightspeed Commerce Reports Second-Quarter Loss per Share
M impact | EQUITY | Nov 05, 2026, 12:22 PM UTC
Evolent Health Reports Third-Quarter Revenue of $725.37 Million
Revenue rose 51.3% year over year as the net loss narrowed. Growth reflected Performance Suite contract go-lives and expanded oncology services, partly offset by lower membership a
M impact | EQUITY | Nov 05, 2026, 12:19 PM UTC
Commerce Reports Third-Quarter 2026 Revenue of $84.25M, EPS Loss of $0.04
Revenue declined year over year as lower partner and services revenue more than offset slightly higher subscription solutions revenue. The company reported a wider net loss.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Molson Coors Reports Q3 Earnings, Lowered 2026 Outlook
Molson Coors reported Q3 non-GAAP earnings; net sales fell and the company lowered its 2026 outlook.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Shutterstock Reports Third-Quarter Revenue of $173.9 Million and EPS of ($5.35)
Third-quarter revenue fell 33% year over year, and Shutterstock swung to a net loss from income a year earlier. Lower new-customer acquisition weighed on Content, while Data, Distr
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Malibu Boats reports first-quarter earnings
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC